PDB24 DIRECT HEALTHCARE AND INDIRECT WORKLOSS COSTS ASSOCIATED WITH THE ADDITION OF ROSIGLITAZONE (RSG) VERSUS SITAGLIPTIN (STG) THERAPY TO METFORMIN (MET)
Abstract
Authors
P. Lefebvre S.P. Sarda F. Laliberté P. Ramamurthy R. Wei B. Arondekar L. Menditto A.A. Martin M.S. Duh